By targeting the retina’s protective barrier, oral Danegaptide could help treat diabetic eye damage earlier, though its lasting benefits remain to be tested. For millions of people with diabetes, treating vision-threatening eye damage means waiting until vision loss has already…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.